Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Scott

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Pathology|October 31, 2018
Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancerTuan Zea Tan, Valerie Heong, Jieru Ye, et al.
JCO Precision Oncology|February 1, 2022
MEK Inhibitor Therapy in Carcinomas With <i>RAF1</i> Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell CarcinomaChristopher R McEvoy, Damien Kee, Owen W J Prall, et al.
Molecular Oncology|December 15, 2018
The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinomaMing Tan, Mohammad Asad, Valerie Heong, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Investigating the phylogenetic history of toxin tolerance in mushroom-feeding <i>Drosophila</i>Theresa Erlenbach, Lauren Haynes, Olivia Fish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare CancersOliver Klein, Damien Kee, Ben Markman, et al.
The New England Journal of Medicine|March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal for Immunotherapy of Cancer|November 16, 2021
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trialOliver Klein, Damien Kee, Bo Gao, et al.
British Journal of Cancer|January 19, 2019
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancerChee Khoon Lee, Clare Scott, Geoffrey J Lindeman, et al.
Virchows Archiv : an International Journal of Pathology|August 12, 2019
Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinomaStefan Porubsky, Peter Jessup, Damien Kee, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Pathology|October 31, 2018
Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancerTuan Zea Tan, Valerie Heong, Jieru Ye, et al.
JCO Precision Oncology|February 1, 2022
MEK Inhibitor Therapy in Carcinomas With <i>RAF1</i> Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell CarcinomaChristopher R McEvoy, Damien Kee, Owen W J Prall, et al.
Molecular Oncology|December 15, 2018
The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinomaMing Tan, Mohammad Asad, Valerie Heong, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Investigating the phylogenetic history of toxin tolerance in mushroom-feeding <i>Drosophila</i>Theresa Erlenbach, Lauren Haynes, Olivia Fish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare CancersOliver Klein, Damien Kee, Ben Markman, et al.
The New England Journal of Medicine|March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal for Immunotherapy of Cancer|November 16, 2021
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trialOliver Klein, Damien Kee, Bo Gao, et al.
British Journal of Cancer|January 19, 2019
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancerChee Khoon Lee, Clare Scott, Geoffrey J Lindeman, et al.
Virchows Archiv : an International Journal of Pathology|August 12, 2019
Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinomaStefan Porubsky, Peter Jessup, Damien Kee, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Pageof 6